glp 1 kaiser permanente glp-1 📌 Starting January 1, 2025, Kaiser Permanente will be making adjustments to the coverage of GLP-1 drugs and other Anti-Obesity Medications (AOMs) in California commercial Prescribing GLP-1s: Evidence, limits, expectations

It is licensed for use in T2D as an add-on therapy to metformin, sulphonylureas, pioglitozone or long-acting insulin only

however, some are acutely aware of these signals

[36], in a real-world cohort treated with GLP-1 RAs including exenatide, observed a mean BW loss of 2.5 kg and a BMI reduction of 0.9 kg/m without a significant change in intrahepatic lipid content, reflecting variability in hepatic responses across populations

So more commonly, in the lay press, the Ozempics, the Wegovy, the Zepbound or tirzepatide products that are approved currently for the treatment of type 2 diabetes and weight loss. Cahill said the research team got into this line of investigation because groups in Boston and research teams around the globe have shown that diabetics who are treated with these therapies and have asthma seem to have reduced asthma exacerbations

"In both age groups, the last dispensed prescription in 2023 was most commonly for injectable semaglutide [Ozempic] for Type 2 diabetes," Lee's group noted

No, there is no nationwide change taking effect on April 1, 2026, that expands coverage for these medications